Tuesday, March 21, 2023
Clinical Advances in
The treatment landscape for asthma continues to evolve, with recent advances in therapies and inhaler technology. Triple fixed-dose ICS/LABA/LAMA therapy has demonstrated improved asthma outcomes vs dual therapy. Biologics have shown clinical benefits in severe asthma and a common comorbidity, CRSwNP. The COVID-19 pandemic poses an additional challenge. Clinicians need guidance in optimizing therapy based on disease characteristics, comorbidities, and patient preferences, so they can effectively control asthma by implementing the latest clinical evidence into their treatment decision making process.
Supported by independent funding from
Test your knowledge against your peers in a series of 2-3 minute medical questions.
Downloadable slides on moderate to severe asthma, dual bronchodilation therapy, CRSwNP and COVID-19
Download
Omalizumab efficacy and safety in nasal polyposis: results from two parallel, double-blind placebo-controlled trials.
Indacaterol/glycopyrronium/mometasone furoate improves lung function and reduces exacerbations versus long-acting β2-agonist/inhaled corticosteroid standard-of-care in patients with uncontrolled asthma: the phase III IRIDIUM study.
Non-inferior improvement in asthma quality of life and favourable benefit in terms of lung function and asthma control with inhaled combination of indacaterol/glycopyrronium/mometasone furoate once daily compared with the "loose" combination of salmeterol/fluticasone twice daily plus tiotropium in patients with uncontrolled asthma: results of the phase III ARGON study.
See All
Head
Upper Airways Research Laboratory
Chief
Clinics ENT-Department
University Hospital Ghent
Ghent, Belgium
Associate Professor of Internal Medicine
Department of Biomedical Science
Humanitas University
Pieve Emanuele, Milan, Italy
Professor of Respiratory Medicine
Université Paris-Saclay
Department of Respiratory and Intensive Care Medicine
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
Professor Emeritus of Rhinology
University College London
London, United Kingdom
Professor of Respiratory Medicine
Head
Respiratory Division
National Heart and Lung Institute
Imperial College London
London, United Kingdom
President, Central Health Council
Director, 7th Respiratory Medicine
Department and Asthma Center,
Greece
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca; GlaxoSmithKline; Novartis; Sanofi
Served as a speaker or a member of a speakers bureau for: Idem
Received grants for clinical research from: Sanofi
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca; Circassia; GlaxoSmithKline; Nestle Purina; Novartis; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca; Circassia; Nestle Purina; Novartis; Sanofi
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca; GlaxoSmithKline; Merck; Novartis; Roche; Sanofi; Teva
Served as a speaker or a member of a speakers bureau for: AstraZeneca; GlaxoSmithKline; Merck; Novartis; Roche; Sanofi; Teva
Received grants for clinical research from: GlaxoSmithKline; Novartis
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Novartis
Served as a speaker or a member of a speakers bureau for: Abbott
Has disclosed the following relevant financial relationships:
Received grants for clinical research from: AstraZeneca; Boehringer Ingelheim; Chiesi; GlaxoSmithKline; Novartis
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: GSK, Novartis, Menarini, Chiesi, BMS, MSD
Served as a speaker or a member of a speakers bureau for: Chiesi, Elpen, GSK, Menarini, Pharmaten
Received grants for clinical research from: Novartis, AZ, Galapagos, Roche
